PROTAGONIST THERAPEUTICS Trademark

Trademark Overview


On Friday, March 3, 2023, a trademark application was filed for PROTAGONIST THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the PROTAGONIST THERAPEUTICS trademark a serial number of 97822178. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, March 12, 2024. This trademark is owned by PROTAGONIST THERAPEUTICS, INC.. The PROTAGONIST THERAPEUTICS trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceuticals for use in the treatment of cancer and blood diseases and disorders; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of metabolic disorders

Providing healthcare information to healthcare professionals and patients relating to disease states and treatment options; Medical information services in the fields of pharmaceuticals, oncology, and blood diseases and disorders

Medical research and medical research information services in the fields of pharmaceuticals, oncology, and blood diseases and disorders; Scientific research, pharmaceutical research, medical research; technical consultation services in the field of research and product development for the treatment of immune mediated diseases, inflammatory diseases, oncological disorders and rare diseases; scientific consultation services in the fields of immune mediated diseases, inflammatory diseases, oncological disorders and rare diseases; product development services for others in the fields of immune mediated diseases, inflammatory diseases, oncological disorders and rare diseases; research and development of new products pertaining to the treatment of immune mediated diseases, inflammatory diseases, oncological and rare diseases
protagonist therapeutics

General Information


Serial Number97822178
Word MarkPROTAGONIST THERAPEUTICS
Filing DateFriday, March 3, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, March 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 29, 2023

Trademark Statements


Goods and ServicesPharmaceuticals for use in the treatment of cancer and blood diseases and disorders; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of metabolic disorders
Goods and ServicesProviding healthcare information to healthcare professionals and patients relating to disease states and treatment options; Medical information services in the fields of pharmaceuticals, oncology, and blood diseases and disorders
Disclaimer with Predetermined Text"THERAPEUTICS"
Goods and ServicesMedical research and medical research information services in the fields of pharmaceuticals, oncology, and blood diseases and disorders; Scientific research, pharmaceutical research, medical research; technical consultation services in the field of research and product development for the treatment of immune mediated diseases, inflammatory diseases, oncological disorders and rare diseases; scientific consultation services in the fields of immune mediated diseases, inflammatory diseases, oncological disorders and rare diseases; product development services for others in the fields of immune mediated diseases, inflammatory diseases, oncological disorders and rare diseases; research and development of new products pertaining to the treatment of immune mediated diseases, inflammatory diseases, oncological and rare diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 23, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, March 23, 2023
Primary Code042
First Use Anywhere DateTuesday, August 22, 2006
First Use In Commerce DateTuesday, August 22, 2006

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, March 23, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePROTAGONIST THERAPEUTICS, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNewark, CA 94560

Party NamePROTAGONIST THERAPEUTICS, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNewark, CA 94560

Trademark Events


Event DateEvent Description
Wednesday, March 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 12, 2024SOU EXTENSION 1 GRANTED
Tuesday, March 12, 2024SOU EXTENSION 1 FILED
Tuesday, March 12, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 24, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 29, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 29, 2023PUBLISHED FOR OPPOSITION
Wednesday, August 9, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, July 20, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, July 18, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 17, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 17, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 3, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 3, 2023NON-FINAL ACTION E-MAILED
Monday, July 3, 2023NON-FINAL ACTION WRITTEN
Sunday, June 25, 2023ASSIGNED TO EXAMINER
Thursday, March 23, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 7, 2023NEW APPLICATION ENTERED